Relative efficacy and safety of simeprevir and telaprevir in treatment-naïve hepatitis C-infected patients in a Japanese population: A Bayesian network meta-analysis

Hepatology Research

Volumn 45, Issue 10, 2015, Pages E89-E98

  Quigley, Joan M ^a   Bryden, Peter A ^b   Scott, David A ^a   Kuwabara, Hiroyo ^d   Cerri, Karin ^c,e  

^a ICON PLC   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^d Janssen Pharmaceutical KK   (Japan)

^e JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Hepatitis C; Network meta analysis; Simeprevir; Telaprevir

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN; SIMEPREVIR; TELAPREVIR;

ANEMIA; ARTICLE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEPATITIS C; HUMAN; INTENTION TO TREAT ANALYSIS; JAPANESE (PEOPLE); META ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

EID: 84945494886     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12467     Document Type: Article

References (43)

1. WHO. WHO Hepatitis C Fact Sheet. 2011; Available at: http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed July 2014.
2. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50years in Japan. Intervirology 2010; 53: 39-43.
3. Liu GG, DiBonaventura M, Yuan Y, Wagner JS, L'Italien GJ, Langley P, Kamae I. The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan. Value Health 2012; 15(Suppl 1): S65-S71.
4. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009; 44(Suppl 19): 102-107.
5. Ikai I, Arii S, Okazaki M etal. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007; 37: 676-691.
6. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009; 24: 346-353.
7. GLOBOCAN. GLOBOCAN 2012; Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. 2012.
8. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009; 24: 336-345.
9. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
10. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
11. Arase Y, Kumada H. Treatment strategy for chronic hepatitis C in Japan. Nihon Rinsho 2011; 69(Suppl 4): 180-184.
12. Izumi N. Diagnostic and treatment algorithm of the Japanese society of hepatology: a consensus-based practice guideline. Oncology 2010; 78 (Suppl 1): 78-86.
13. Editors of the Drafting Committee for Hepatitis Management Guidelines: The JapanSociety of Hepatology, The Japan Society of Hepatology, Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, Hepatol Res 2013; 43: 1-34.
14. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
15. EASL. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.
16. Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 2014; 49: 138-147.
17. Hayashi N, Izumi N, Kumada H etal. Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014. doi: 10.1016/j.jhep.2014.04.004
18. CRD. Systematic Reviews: CRD's guidance for undertaking systematic reviews in health care. 2009.
19. FDA. Guidance for industry. Chronic Hepatitis C infection: developing direct-acting antivirals drugs for treatment. 2013
20. Chen J, Florian J, Carter W etal. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013; 144: 1450-1455.
21. Sitole M, Silva M, Spooner L, Comee MK, Malloy M. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Clin Ther 2013; 35: 190-197.
22. Cooper CL, Druyts E, Thorlund K etal. Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. Ther Clin Risk Manag 2012; 8: 105-130.
23. Cooper C, Lester R, Thorlund K, etal. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM 2013; 106: 153-163.
24. Higgins JPT, Green S. Assessing risk of bias in incldued studies. In: Higgins JPT, Altman DG, Sterne JAC, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, Chichester, England: John Wiley & Sons Ltd. 2011.
25. Gemeinsamer Bundesausschuss . Chapter 5: Assessment of the benefits of Pharmaceuticals according to § 35a SGB V. 2012 Available at: http://www.english.g-ba.de/downloads/17-98-3042/2011-05-18_5%20Kapitel%20VerfO%20Englisch.pdf. Accessed on 5/1/2012.
26. NICE. Guide to the methods of technology appraisal 2013. 2013.
27. Hoaglin DC, Hawkins N, Jansen JP etal. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011; 14: 429-437.
28. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005; 331: 897-900.
29. Hasselblad V. Meta-analysis of multitreatment studies. Med Decis Making 1998; 18: 37-43.
30. Jansen JP, Fleurence R, Devine B etal. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011; 14: 417-428.
31. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med 2005; 24: 2401-2428.
32. Spiegelhalter DJ, Best NJ, Carlin BP, Van der Linde A. A: Bayesian Measures of model complexity and fit (with discussion). J R Stat Soc 2002; 64: 583-639.
33. Brooks SP, Gelman A. General Methods for Monitoring Convergence of Iterative Simulations. J Comput Graph Stat 1998; 7: 434-455.
34. Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of Pegylated interferon alpha-2a and alpha-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infect Dis 2012; 12: 357. doi: 10.1186/1471-2334-12-357.
35. Dogan UB, Atabay A, Akin MS, Yalaki S. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1. Eur J Gastroenterol Hepatol 2013; 25: 1082-1085.
36. Editors of the Drafting Committee for Hepatitis Management Guidelines: The Japan Society of Hepatology, The Japan Society of Hepatology. Guidelines for the Management of Hepatitis C virus Infection First edition, May 2012. Hepatol Res 2013; 43: 1-34.
37. Drafting Committee for Hepatitis Management Guidelines: The Japan society of Hepatology. Guidelines for the Management of Hepatitis C virus Infection: A 2014 update for Genotype 1. Hepatol Res 2014; 44: 59-70.
38. Paul RB, Lyle CG, Michael JC. Clinical significance not statistical significance: a simple Bayesian alternative to p values. J Epidemiol Community Health 1998; 52:318-323.
39. Frusyo N, Ogawa E, Nakamuta M etal. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol 2013; 59:205-212.
40. Sezaki H, Suzuki F, Hosaka T etal. Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients. Hepatol Res 2014; 44:E163-E171.
41. Shrier I, Boivin JF, Steele RJ etal. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. Am J Epidemiol 2007; 166: 1203-1209.
42. McHutchison JG, Everson GT, Gordon SC etal. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
43. Jacobson IM, McHutchison JG, Dusheiko G etal. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.